Docket No. 2324-6003US1

Applicant(s):

Francis J. MICHON

Serial No.:

Not yet assigned

27123

Group Art Unit:

Not yet assigned

Filed:

Herewith (December 21, 2005)

Examiner:

Not yet assigned

For:

VACCINES AGAINST GROUP Y NEISSERIA MENINGITIDIS AND

Pursuant to Rule 56, applicant hereby calls the attention of the Patent Office to the references

MENINGOCOCCAL COMBINATIONS THEREOF

Customer No.:

INFORMATION DISCLOSURE STATEMENT

Mail Stop PCT Commissioner for Patents P.O. Box 1450

Alexandria, VA 22313-1450 Sir:

listed c	on the attached Forms PTO 1449A and PTO 1449B. Copies of these references 🔀 are attached
herewi	th, except US Patents and U.S. Patent Publications, and/or were filed in related application
U.S. Se	erial No(s), filed, respectively.
	This document is being filed within three (3) months of the filing date of the application Please charge the \$180 fee to Deposit Account No. 13-4500, Order No This document is being concurrently filed with the above-identified application This document is being concurrently filed with an Request for Continued Examination (RCE) This document is being filed prior to a first Office Action This document is accompanied by a Search Report cited in a corresponding PCT counterpart application.
X	The Commissioner is hereby authorized to charge any additional fees which may be required for this Information Disclosure Statement, or credit any overpayment to Deposit Account No. 13-4500, Order No. 2324-6003US1. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

Respectfully submitted,

MORGAN & FINNEGAN, L.L.P.

Dated: December 21, 2005

Registration No. 54,246

Correspondence Address: MORGAN & FINNEGAN, L.L.P.

3 World Financial Center New York, NY 10281 2101 212 415 8700 Telephone Facsimile 212 415 8701

FORM PTO-1449A INFORMATION DISCLOSURE CITATION				Attorney Docket: 2324-6003US1			Serial 10/562261			
				Appli	Applicant:					
				Filing	Francis J. MICHON Filing Date:			Group Art Unit:		
			**	Herev	vith (December 21	, 2005)	TBA			
Examiner			S.PATENŢ.	/ PUBL	ICATION DOC	DWIEW I	S		Filing	
Initial	v	Patent/Publication N	lumber I	Publicat	tion/Issue Date		Na	me	Date	
								•		
		· · · · · · · · · · · · · · · · · · ·								
								· · · · · · · · · · · · · · · · · · ·	-	
					· · · · · · · · · · · · · · · · · · ·					
	Little 2012 Septem				eror vaccourants and a line of the ball and	da Kasabara k				
			erecess to account the tradition	TABLE DESIGNATIONS DE	ENT DOCUME!	YTS				
Examiner Initial		Patent Number	Publica Date		Country	,	Copy Filed	Transla	ion	
	1.	94/05325	March 17,	1994	wo		⊠ Yes	☐ Yes ☐ No ☐ A	bstract ⊠N/A	
	2.	00/10599	March 2, 2	000	wo		⊠ Yes	☐ Yes ☐ No ☐ A	bstract ⊠N/A	
	3.						☐ Yes	☐ Yes ☐ No ☐ A	bstract □N/A	
	4.			_			☐ Yes	☐ Yes ☐ No ☐ A	bstract □N/A	
:	5.						Yes	☐ Yes ☐ No ☐ A	bstract □N/A	
	6.						☐ Yes	☐ Yes ☐ No ☐ A	bstract □N/A	
		•								
Examiner					Date Considered	i .				
EXAMINER:	Draw	if reference considered, wheth	onformance and	not consi	dered.	§609.				

JAP6 Rec'd PCT/PTO 21 DEC 2005

Page 1 of 1

	FORM F	PTO-1449B	Attorney Docket: 2324-6003US1	Serial N 10/562261			
			Applicant:				
INFORMATION DISCLOSURE CITATION			Francis J. MICHON				
			Filing Date: Group Art Unit:				
			Herewith (December 21, 2005)	TBA			
		C	THER DOCUMENTS				
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					
			al., "Structural Determination Of T				
		Neisseria Meningitidis S	erogroup Y Serogroup W-135 And	Serogroup BO ¹ ", Canadian			
	1.	Journal Of Biochemistry	, Vol. 54, No. 1, Pages 1-8, January	1976.			
	-	JONES, et al., "Use And	Validation Of NMR Assays For T	he Identity And O-acetyl Content			
		Of Capsular Polysacchar	ides From Neisseria Meningitidis U	Jsed In Vaccine Manufacture",			
•		Journal Of Pharmaceutic	al And Biomedical Analysis, Vol.:	30, No. 4, Pages 1233-1247,			
	2.	November 2002.					
	ł	HRONOWSKI, et al., "E	-75: Structure Activity Studies On	Neisseria Meningitidis Group C			
		Polysaccharide-Protein C	Conjugate Vaccines: The Effect of of	O-acetylation On The Antibody			
	3.		<u>ciety For Microbiology,</u> Vol. 93, P				
	1	FARLEY, et al. "G-1647	: Preclinical Studies On The Devel	opment Of An Optimal			
		Meningococcal CYW Co	njugate Vaccine", Antimicrobial A	agents and Chemotherapy, Vol.			
	4.	1 , 8 ,					
			: Effect Of O-acetylation Of Neiss				
			On Development Of Functional A	ntibodies", Antimicrobial Agents			
	5.	and Chemotherapy, Vol.	43, Page 292, 2003.				
	6.	International Search Rep	ort for PCT/US2004/020048, dated	December 9, 2004.			

Examiner	Date
Signature	Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.